MBRX

Moleculin Biotech (MBRX)

Moleculin Biotech Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MBRX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	21 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/16	21 : 32	PR Newswire (US)	Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/15	21 : 38	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/15	21 : 38	PR Newswire (US)	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/15	05 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/13	23 : 53	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/13	20 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/13	20 : 30	PR Newswire (US)	Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/11	05 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/09	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/09	21 : 30	PR Newswire (US)	Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/08	21 : 45	PR Newswire (US)	Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/08	21 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/08	05 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/07	21 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/07	21 : 55	PR Newswire (US)	Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/02	22 : 00	PR Newswire (US)	Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024	NASDAQ:MBRX	Moleculin Biotech Inc
2024/05/01	21 : 50	PR Newswire (US)	Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin	NASDAQ:MBRX	Moleculin Biotech Inc
2024/04/18	21 : 30	PR Newswire (US)	European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)	NASDAQ:MBRX	Moleculin Biotech Inc
2024/04/10	21 : 30	PR Newswire (US)	Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/28	23 : 45	PR Newswire (US)	Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/27	22 : 25	PR Newswire (US)	Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/27	22 : 05	PR Newswire (US)	Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/25	20 : 30	PR Newswire (US)	Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/23	05 : 05	PR Newswire (US)	Moleculin Reports Full Year 2023 Financial Results	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/20	20 : 30	PR Newswire (US)	Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/20	20 : 15	IH Market News	JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/20	05 : 30	PR Newswire (US)	Moleculin Announces Reverse Stock Split	NASDAQ:MBRX	Moleculin Biotech Inc
2024/03/12	22 : 05	PR Newswire (US)	Moleculin to Present at the 36th Annual ROTH Conference	NASDAQ:MBRX	Moleculin Biotech Inc
2024/02/29	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MBRX	Moleculin Biotech Inc